Background
==========

Chronic obstructive pulmonary disease (COPD) is a leading chronic condition in many countries \[[@B1]\]. Patients can experience exacerbation of COPD (eCOPD) that often requires assessment in an emergency department (ED) and hospitalization. Exacerbations play a major role in the burden of COPD, its evolution, and its cost \[[@B2],[@B3]\]. Some exacerbations can be severe, leading to death or the need for intubation, whereas others are more moderate, requiring little more than an adjustment of the patient's current medical therapy. Currently, ED physicians must rely largely on their experience and the patient\'s personal criteria for gauging how an eCOPD will evolve. A clinical prediction rule that could help predict eCOPD evolution would allow ED physicians to make better informed decisions about treatment.

A couple of severity scores have been developed for patients with stable COPD \[[@B4],[@B5]\], but these do not apply to patients with eCOPD. Several studies have attempted to develop severity scores for eCOPD, but none has been adopted by clinicians, largely because they do not include important clinical variables or they have other methodological problems \[[@B6]-[@B10]\]. Several key issues affect the development of severity scores for patients with eCOPD being evaluated in an ED. To date, most such studies have included only patients who are admitted to the hospital, which excludes a significant percentage of patients with eCOPD \[[@B11],[@B12]\]. Another limitation is the choice of reliable predictors that can easily be gathered in the ED. For a clinical prediction rule to be adopted, its development must follow strict methodological norms and must be based on easily available parameters \[[@B13],[@B14]\].

The goal of this study was to develop a clinical prediction rule for short-term death following eCOPD. We defined \'short term \'as any time during the hospital admission or within 1 week after discharge from the ED to home. Data for developing this rule were collected from a large prospective cohort of patients with eCOPD attending a number of different EDs.

Methods
=======

This prospective cohort study covered 16 hospitals belonging to the Spanish National Health Service (Hospital Costa del Sol, Hospital Valme, Hospital de Motril, Corporació Sanitaria Parc Taulí, Hospital del Mar, Hospital Universitario de La Princesa, Hospital Universitario Gregorio Marañón, Hospital Universitario La Paz, Hospital de Móstoles, Hospital Marqués de Valdecilla, Hospital Santa Marina, Hospital San Eloy, Hospital Galdakao-Usansolo, Hospital Txagorritxu, Complejo Hospitalario Donostia, and Hospital Cruces). The Institutional Review Boards of the participating hospitals approved this project. Patients with eCOPD attending the EDs of any of these hospitals were informed of the goals of the study, and invited to voluntarily participate and sign an informed consent form. All information was kept confidential. Recruitment started in June 2008 and ended in September 2010. A description of the study protocol was published previously \[[@B15]\].

Patients were eligible for the study if they presented to the ED with symptoms consistent with eCOPD. COPD was confirmed if the patient had a forced expiratory volume in 1 second/forced vital capacity (FEV~1~/FVC) quotient of less than 70%. Exacerbation was defined as an event in the natural course of the disease characterized by a change in the patient's baseline dyspnea, cough, and/or sputum that was beyond normal day to day variations and may have warranted a change in regular medication in a patient with underlying COPD \[[@B16]\]. For cases of COPD newly diagnosed in the ED to be included in the study, they had to be confirmed by spirometry within 60 days after the index episode at a time when the patient was stable \[[@B17]\]. Patients were excluded from the study if, at the time they were seeing at the ED, they had eCOPD complicated by a comorbidity such as pneumonia, pneumothorax, pulmonary embolism, lung cancer, or left cardiac insufficiency. Other exclusion criteria included a diagnosis of asthma, extensive bronchiectasis, sequelae of tuberculosis, pleural thickening, or restrictive disease. Patients who did not wish to participate were also excluded.

Data collected
--------------

Data collected upon arrival in the ED included socioeconomic data, information about the patient's respiratory function (arterial blood gases, respiratory rate, dyspnea), consciousness level measured by the Glasgow Coma Scale (GCS; altered consciousness defined as a score of ≤15 points, unaltered consciousness as a score of \>15) \[[@B18]\], and presence of other pathologies recorded in the Charlson Comorbidity Index \[[@B19]\]. Additional data collected in the ED at the time a decision was made to admit or discharge the patient included the patient's symptoms, signs, and respiratory status at that time. All information regarding the ED evaluation was recorded as it was provided by the ED physician in charge of the patient.

For patients admitted to the hospital, we collected additional data from the patient's medical record and from a direct interview with the patient on the first day after admission and on the day of discharge. For patients discharged from the ED to home, telephone interviews were conducted with the patient around 1 and 7 days after discharge to assess hospital readmission and vital status. We asked all patients to tell us about their physical activity, general health, and dyspnea level while in stable condition before the eCOPD index and at 24 hours after being admitted to the hospital or discharged from the ED to home. We used the Medical Research Council (MRC) breathlessness scale \[[@B20]\] to measure baseline dyspnea.

For all patients with known COPD, additional variables were collected from medical records, including baseline severity of COPD as measured by FEV~1~; hospital admissions for eCOPD during the previous 12 months; baseline therapy (inhaled short-acting or long-acting beta-agonist, short-acting or long-acting anticholinergics, oral or inhaled corticosteroid, theophyllines, and/or need for noninvasive mechanical ventilation (NIMV) or long-term home oxygen therapy (LTHOT)); and presence of diabetes, hypertension, ischemic heart disease and/or valve disease, cor pulmonale, hepatic disease, peptic ulcer disease, psychiatric disorders, rheumatic disease, and any history of stroke or deep-vein thrombosis, and of other conditions needed to determine the Charlson Comorbidity Index.

Reviewers were trained before data collection, and a precise manual was developed, which was closely followed for the collection of data.

Definitions of outcome measure
------------------------------

The main outcomes measured were death occurring during the hospital admission or within 1 week of discharge to home from the ED, and death within 1 month of the index ED visit. Additional outcomes reported in this study were admission to the hospital and, if admitted, length of hospital stay; admission to the intensive care unit (ICU); need for invasive mechanical ventilation (IMV); need for NIMV for 2 or more days when mechanical ventilation was not used at home before admission; and admission to an intermediate respiratory care unit (IRCU) for 2 or more days (a minimum of 2 days was chosen to include only those patients needing more intensive and prolonged therapeutic interventions).

Patients were followed by phone or direct interview to reduce losses to a minimum.

Statistical analysis
--------------------

The unit of the analysis was the patient. For patients who had more than one eCOPD requiring an ED visit during the recruitment period, only the first visit was considered for the analysis. Assumptions about how missing data were handled in this study have been described elsewhere. In general, missing values were imputed. In the case of missing data on basal level of dyspnea (MRC classification) it was imputed because class 5 comparison of the mortality rate of this group of patients with the other MRC categories (1 to 4) gave *P* values of less than 0.0001, whereas the *P* value within the MRC group 5 was 0.63.

The total sample was randomly divided in two to give a derivation sample and a validation sample. Descriptive analyses for both samples included frequency and percentages for categorical variables, and mean and standard deviations for continuous variables. The χ^2^and Fisher's exact tests were used to test for statistical significance between proportions. For continuous variables, the Wilcoxon U-test was used.

In order to identify risk factors associated with short-term mortality in COPD, we performed univariate analyses in the derivation sample using logistic regression. Variables that were significant at *P* = 0.20 were entered into a multivariate logistic regression model. We performed logistic regression models in the derivation sample to select separately the variables for prediction of death. Final predictive factors in the multivariate analysis were those with a significance level of 0.05. Beta estimates, odds ratios (ORs) and 95% confidence intervals (95% CIs) were provided for the multivariate analysis. We developed a score by assigning a weight to each risk factor category based on the β parameter from the multivariate logistic regression. From the continuous score, four risk categories were created (mild, moderate, severe, and very severe). We considered the optimal classifier point as the point that maximized the sum of sensitivity and specificity. Final models were also adjusted by the treating hospital to see if that affected the results.

The predictive accuracy of each model was determined by calculating the area under the receiver operating characteristic (ROC) curve (discrimination) (AUC), and the models were calibrated by means of the Hosmer and Lemeshow test. We validated all AUCs---that is, those from the model and those from the continuous and categorical scores---in the validation sample by deriving the AUC in this sample \[[@B21]\].

Additional multivariate logistic regressions models were performed to evaluate the impact on short-term mortality of arterial blood gas values (pH, PCO~2~ and PO~2~) measured both at the time the patient arrived in the ED and at the time a decision was made to hospitalize the patient or discharge them to home from the ED. These were adjusted by our categorical score.

We compared various outcomes between the four risk classes of our categorical score. These included ICU admission; need for IMV; admission to an IRCU; admission to the hospital and, if admitted, length of hospital stay; readmissions within 10 days, 1 month, and 2 months after the index ED visit; and subsequent ED visits in the 2 months following the index ED visit.

To compare the predictive ability of our score, we applied information from all patients to previously created predictor scores for mortality in patients with stable COPD. These included the ADO (age, baseline dyspnea, and airflow obstruction measured by FEV1%) index \[[@B22]\], the HADO (health, activity, dyspnea, and airflow obstruction) score \[[@B23]\], baseline FEV1% classified according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) standards (FEV1% alone) \[[@B16]\], and the GOLD COPD combined assessment (baseline dyspnea plus previous exacerbations over the previous year) \[[@B24]\]. For the latter, we used hospitalizations during the previous year, as we did not collect the variable \'previous exacerbations.\' Descriptive statistics for the previous mortality predictor scales (FEV1% classifications) were computed, and each AUC and its CI were determined and compared with our score.

All effects were considered significant at P \< 0.05, unless otherwise stated. All statistical analyses were performed using SAS for Windows statistical software, v9.2 (SAS Institute, Inc., Carey, NC) and R^©^ software v2.13.0.

Results
=======

A total of 3,276 episodes were assesses for the study. Of these, 198 (6%) were excluded because COPD was complicated by other major pathologies at the time of ED admission (cardiovascular conditions: 59 (29.8%); pneumonia: 55 (27.8%); cancer: 21 (10.6%); other respiratory problems, 13 (6.6%); and other conditions, 50 (25.2%)). A further 56 episodes were excluded because the COPD diagnosis was not confirmed by spirometry within 60 days of the index episode. Another 145 episodes were lost because of incomplete data without the possibility of retrieving the information needed for the study. Finally, 390 episodes were excluded because the patient had more than one ED visit. No differences were observed in mortality (4.4% *versus*. 2.7%; *P* = 0.32) or other parameters, such as arterial blood gas as pH upon ED arrival (*P* = 0.52) between episodes excluded because patients had multiple eCOPD episodes and episodes included from patients who had only a single eCOPD episode.

The final population included 2,487 patients. Of these, 1,537 (61.8%) were admitted to the hospital and 950 (38.2%) were discharged from the ED to home.

Comparison of the derivation and validation samples is shown in Table  [1](#T1){ref-type="table"}. Variables related to short-term mortality in the univariate analysis of the derivation sample are displayed in Table  [2](#T2){ref-type="table"}. Variables that were also evaluated, but were not statistically significantly correlated with outcome, included previous oral corticosteroid use, chronic renal disease, cerebrovascular disease, chronic liver disease, edema at ED admission, and four variables recorded upon ED arrival:O~2~ saturation, blood pressure, temperature, and serum glucose.

###### 

Descriptive characteristics of derivation and validation samples

                                                                     **Derivation**   **Validation**   ***P*value**                  
  ----------------------------------------------------------------- ---------------- ---------------- -------------- --------------- ------
  Age, years^b^                                                           1242         72.32 ± 9.81        1244       73.23 ± 9.51    0.02
  Male sex                                                                1242         1136 (91.47)        1242       1131 (91.06)    0.72
  Baseline FEV                                                            1046                             1023                         
  ≥50                                                                                  367 (35.09)                     352 (34.41)    0.75
  \<50                                                                                 679 (64.91)                     671 (65.59)      
  Charlson Comorbidity Index^b^                                           1243         2.25 ± 1.55         1244        2.89 ± 1.6     0.79
  Previous use of LTHOT or NIMV at home                                   1243         424 (34.11)         1244        417 (33.52)    0.76
  Number of COPD-related admissions in the previous 12 months^bd^         1228         0.84 ± 1.37         1223        0.83 ± 1.38    0.65
  Altered consciousness                                                   1242          31 (2.50)          1243         39 (3.14)     0.33
  Presence of edema                                                       1164         225 (19.33)         1168        211 (18.07)    0.43
  Dyspnea upon ED arrival                                                 1182         803 (67.94)         1179        798 (67.68)    0.9
  Heart rate upon ED arrival^b^                                           1168        95.51 ± 19.35        1163       94.32 ± 18.69   0.1
  Use of inspiratory accessory muscle upon ED arrival                     1243         248 (19.95)         1244        262 (21.06)    0.49
  Breathing frequency upon ED arrival                                     1135                             1132                       0.8
  \<20 breaths/min                                                                     186 (16.39)                     188 (16.61)      
  20 to 24 breaths/min                                                                 506 (44.58)                     489 (43.2)       
  \>24 breaths/min                                                                     443 (39.03)                     455 (40.19)      
  pH upon ED arrival                                                      1147                             1148                       0.3
  ≥7.35                                                                                986 (85.96)                    1005 (87.54)      
  7.26 to 7.35                                                                         136 (11.86)                     114 (9.93)       
  \<7.26                                                                                25 (2.18)                       29 (2.53)       
  PO~2~ upon ED arrival                                                   1137                             1141                       0.77
  \>60 (O~2~ saturation \>90%)                                                         563 (49.52)                     571 (50.04)      
  45 to 60 (O~2~ saturation \<90%)                                                     420 (36.94)                     427 (37.42)      
  ≤45                                                                                  154 (13.54)                     143 (12.53)      
  PCO~2~ upon ED arrival                                                  1078                             1076                       0.65
  ≤45                                                                                  603 (55.94)                     629 (58.46)      
  45 to 55                                                                              249 (23.1)                     235 (21.84)      
  55 to 65                                                                             127 (11.78)                     114( 10.59)      
  \>65                                                                                  99 (9.18)                       98 (9.11)       
  Baseline dyspnea (MRC scale)                                            1243                             1244                       0.13
  Missing                                                                               121(9.73)                      129(10.37)       
  Grade 1                                                                                 87 (7)                       101 (8.12)       
  Grade 2                                                                              321 (25.82)                     279 (22.43)      
  Grade 3                                                                              247 (19.87)                     254 (20.42)      
  Grade 4                                                                              345 (27.76)                     327 (26.29)      
  Grade 5                                                                               122 (9.81)                     154 (12.38)      
  Outcomes                                                                                                                              
  Short-term mortality^c^                                                 1243          30 (2.41)          1244         29 (2.33)     0.89
  1-month mortality                                                       1243          40 (3.22)          1244         48 (3.86)     0.39

*Abbreviations*: *COPD* chronic obstructive pulmonary disease, *ED* emergency department, *FEV* forced expiratory volume, *LTHOT* long-term home oxygen therapy, *NIMV* non-invasive mechanical ventilation, *PCO*~*2*~ carbon dioxide partial pressure, *PO*~*2*~ oxygen partial pressure.

^a^Unless otherwise specified.

^b^Mean ± SD.

^c^During hospital admission or within 1 week of discharge to home from the ED.

^d^Number of COPD-related admissions in the previous 12 months, median (25th to 75th percentile): 0 (0--1) in both samples.

###### 

Predictors of short-term mortality and 1 month mortality in the derivation sample

  **Parameter**                                                     **Short-term mortality**^**a**^   **1 month mortality**           
  ---------------------------------------------------------------- --------------------------------- ----------------------- -------- ----------
  Age, years^b^                                                                  1.051                       0.0237           1.0411    0.0294
  Male sex                                                                       1.314                       0.7120            1.8      0.4226
  Baseline FEV: \<50 *versus* ≥50                                                2.197                       0.1185           2.587     0.0365
  Charlson Comorbidity Index^b^                                                  1.297                       0.0016           1.360    \<0.0001
  Previous use of LTHOT or NIMV at home                                          4.690                       0.0001           4.755    \<0.0001
  Number of COPD-related admissions in the previous 12 months^c^                 1.168                       0.1502           1.137     0.187
  Altered consciousness                                                          11.87                      \<0.0001          8.308    \<0.0001
  Presence of edema                                                              1.056                       0.9140           1.246     0.6268
  Dyspnea upon ED arrival                                                        3.531                       0.0414            1.92     0.1268
  Heart rate upon ED arrival^b^                                                  1.028                       0.0017           1.020     0.0128
  Use of inspiratory accessory muscle upon ED arrival                            4.026                       0.0001            2.79     0.0019
  Breathing frequency upon ED arrival                                                                                                      
  20 to 24 *versus* \<20                                                         3.350                       0.2530           2.811     0.1726
  \>24 *versus* \<20                                                             7.381                       0.0529           4.123     0.0585
  pH upon ED arrival                                                                                                                       
  7.26 to 7.35 *versus* ≥7.35                                                    2.631                       0.0456           2.086     0.0931
  \<7.26 *versus* ≥7.35                                                          7.777                       0.0020           7.323     0.0006
  PO~2~ upon ED arrival                                                                                                                    
  45 to 60 *versus* \>60                                                         0.762                       0.5431           0.630     0.2350
  ≤45 *versus* \>60                                                              1.046                       0.9379           0.866     0.7764
  PCO~2~ upon ED arrival                                                                                                                   
  46 to 55 *versus* ≤45                                                         2.8226                        0.047           3.003     0.0115
  56 to 65 *versus* ≤45                                                          0.676                       0.7150           0.949     0.9463
  \>65 *versus* ≤45                                                              8.514                      \<0.0001          7.413    \<0.0001
  Baseline dyspnea (MRC scale)                                                                                                             
  MRC3 *versus* MRC1 to MRC2                                                     6.398                       0.1064           3.335     0.2960
  MRC4 *versus* MRC1 to MRC2                                                     8.035                       0.0397           4.810     0.0601
  MRC5 *versus* MRC1 to MRC2                                                    61.599                      \<0.0001          26.115   \<0.0001
  Missing *versus* MRC1 to MRC2                                                 50.583                      \<0.0001          22.185   \<0.0001

*Abbreviations*: *COPD* chronic obstructive pulmonary disease, *ED* emergency department, *FEV* forced expiratory volume, *LTHOT* long-term home oxygen therapy, *MRC* Medical Research Council, *NIMV* non-invasive mechanical ventilation, *PCO*~*2*~ carbon dioxide partial pressure, *PO*~*2*~ oxygen partial pressure.

^a^Short-term mortality: mortality during hospital admission or, if discharged from the ED, in 1 week.

^b^ Variables included as continuous.

All variables with *P* values below 0.20 were entered into a multivariate logistic regression model. Five parameters shaped the final model for predicting death during hospital admission or within 1 week of discharge from the ED to home: age; previous history of LTHOT or NIMV; altered consciousness measured by GCS; use of accessory inspiratory muscles or paradoxical breathing upon ED arrival; and baseline dyspnea measured by the MRC scale (model AUC = 0.85, 95% CI 0.77 to 0.93). In separate models, we evaluated the effect on the final model of the role of arterial blood gases by adding the values of PO~2~, PCO~2~, and pH measured at both ED arrival and at the time that a decision was made to hospitalize the patient or discharge them from the ED to home. None of these was statistically significant.

We assigned a score to each category of the variables selected in the model based on their parameter estimates. Adding these individual scores yielded a final risk score that we called the continuous death in eCOPD (DeCOPD) risk score (AUC = 0.85, 95% CI 0.77 to 0.93) (Table  [3](#T3){ref-type="table"}). A categorical DeCOPD score was created by dividing the continuous DeCOPD score into four risk categories (mild, moderate, severe, and very severe) based on the risk of experiencing the outcome (Figure  [1](#F1){ref-type="fig"}). This yielded an AUC of 0.84 (95% CI 0.76 to 0.91). Hosmer-Lemeshow tests were all *P* \> 0.62. The continuous DeCOPD score (AUC = 0.84; 95% CI 0.77 to 0.92) and the categorical DeCOPD risk classes (AUC = 0.85; 95% CI 0.78 to 0.92) were validated in a separate sample (validation sample). Introducing the treating hospital variable into any model did not change the model, nor was the individual hospital significantly related to mortality (*P* = 0.064 unadjusted; *P* = 0.96 adjusted by the DeCOPD continuous score).

###### 

Predictors of short-term mortality and 1 month mortality in the derivation sample

  **Outcome prediction model/parameter**                                                                                                **Estimate**   **OR**   **95% CI of the AUC**   ***P*value**   **Score**
  ------------------------------------------------------------------------------------------------------------------------------------- -------------- -------- ----------------------- -------------- -----------
  Short-term mortality^a^                                                                                                                                                                               
  Age, years                                                                                                                                                                                            
  75 to 85 *versus* \<75                                                                                                                0.2417         1.273    0.540 to 3.003          0.5808         0
  \>85 *versus* \<75                                                                                                                    1.3062         3.692    1.134 to 12.022         0.0301         3
  Previous use of LTHOT or NIMV at home                                                                                                 1.1557         3.176    1.278 to 7.893          0.0128         3
  Altered consciousness                                                                                                                 1.1852         3.271    1.031 to 10.376         0.0442         3
  Use of inspiratory accessory muscle or paradoxical breathing upon ED arrival                                                          1.4740         4.367    1.912 to 9.972          0.0005         4
  Baseline dyspnea (MRC scale)                                                                                                                                                                          
  Grade 5 *versus* grades 1 to 4                                                                                                        2.0456         7.734    2.923 to 20.463         \<0.0001       5
  Missing *versus* grades 1 to 4                                                                                                        2.5581         12.912   4.654 to 35.821         \<0.0001       5
  ^b^Derivation sample: AUC~model~ = 0.85 (0.77 to 0.93); AUC~score~ = 0.85 (0.77 to 0.93) AUC~score\ \_\ cat~ = 0.84 (0.76 to 0.91)                                                                   
  ^b^Validation sample: AUC~model~ = 0.88 (0.82 to 0.94); AUC~score~ = 0.84 (0.77 to 0.92) AUC~score\ \_\ cat~ = 0.85(0.78 to 0.92)                                                                    
  1 month mortality (validation sample)                                                                                                                                                                
  Age, years                                                                                                                                                                                            
  75 to 85 *versus* \<75                                                                                                                0.8199         2.270    1.092 to 4.719          0.0281          
  \>85 *versus* \<75                                                                                                                    1.9253         6.857    2.701 to 17.411         \<0.0001        
  Previous use of LTHOT or NIMV at home                                                                                                 1.3737         3.950    1.956 to 7.976          0.0001          
  Altered consciousness                                                                                                                 0.9513         2.589    0.887 to 7.557          0.0817          
  Use of inspiratory accessory muscle or paradoxical breathing upon ED arrival                                                          1.2508         3.493    1.850 to 6.596          0.0001          
  Baseline dyspnea (MRC scale)                                                                                                                                                                          
  Grade 5 *versus* grades 1 to 4                                                                                                        1.1743         3.236    1.581 to 6.625          0.0013          
  Missing *versus* grades 1 to 4                                                                                                        1.3324         3.790    1.643 to 8.742          0.0018          
  ^b^Validation sample: AUC~model~ = 0.85 (0.81 to 0.90); AUC~score~ = 0.83 (0.78 to 0.88); AUC~score\ \_\ cat~ = 0.83 (0.78 to 0.88)                                                                  

*Abbreviations*: *AUC* area under the receiver operating characteristic curve, *LTHOT* long-term home oxygen therapy, *MRC* Medical Research Council, *NIMV* non-invasive mechanical ventilation.

^a^Short-term mortality: mortality during hospital admission or, if discharged from the ED, in 1 week.

^b^AUCs are the results for the whole model, the continuous score, and the categorical score, respectively.

![**Death in exacerbation of chronic obstructive pulmonary disease: construction of continuous and categorical scores and relation with different outcomes.**ICU: Intensive Care Unit, IMV: Invasive mechanical ventilation, IRCU: Intermediate Respiratory Care Unit, LT-HOT: Long-term home oxygen therapy, NIMV: Noninvasive mechanical ventilation. Superscript letters indicated statistical significant differences among the DeCOPD risk classes for the outcomes displayed.](1741-7015-12-66-1){#F1}

The 1-month mortality was tested in the same model. It had an AUC of 0.85 (95% CI 0.81 to 0.90); AUCs were 0.83 (95% CI 0.78 to 0.88) for the continuous DeCOPD score and 0.83 (95% CI 0.78 to 0.88) for the categorical DeCOPD score.

In addition to short-term mortality, other outcomes that reflect adverse eCOPD evolution (for example, need for IMV, admission to ICU or IRCU) were compared between the four risk classes. Differences were observed across most of the categories for such outcomes (Figure  [1](#F1){ref-type="fig"}). Specifically, differences between the four risk classes were observed for short-term mortality, in-hospital mortality, and 1 month mortality. When the four classes were dichotomized in two (score ≥12) the accuracy results for short-term mortality were: sensitivity 41%, specificity 97%, positive predictive value (PPV) 25%, and negative predictive value (NPV) 99%. When the cut-off point was 7 or above, the accuracy results for ICU admission, IMV use, or IRCU admission were: sensitivity 53.9%, specificity 79.05%, PPV 34%, and NPV 89.54%. The relationship of the DeCOPD categorical score in two categories (score ≥7) with other outcomes (for example, hospital admission, length of stay, readmissions or new ED visits) is presented (see Additional file [1](#S1){ref-type="supplementary-material"}).

Finally, we compared the continuous and categorical DeCOPD scores with scores created for patients with stable COPD, including the ADO index, HADO score, GOLD FEV1% and GOLD COPD combined assessment. The AUC of our score was always superior to and statistically significantly different from these other assessments (Table  [4](#T4){ref-type="table"}).

###### 

Comparison of different prediction scales on short-term mortality on patients with eCOPD

  **Outcome**                         **N**   **Short-term mortality**   ***P*value\***   **AUC**   **95% CI**   ***P*value\*\***  
  ---------------------------------- ------- -------------------------- ---------------- --------- ------------ ------------------ ----------
  DeCOPD score mean (sd)              2484          9.03 (4.27)            3.07 (3.4)     ≤0.0001      0.85        0.79 to 0.90      Ref^a^
  DeCOPD score (categorical)          2484                                                ≤0.0001      0.84        0.79 to 0.89       0.38
  Risk                                                                                                                                  
  Mild                                1081            3 (0.28)            1078 (99.72)                                                  
  Moderate                             865           11 (1.27)            854 (98.73)                                                   
  Severe                               441           20 (4.54)            421 (95.46)                                                   
  Very severe                          97            24 (24.74)            73 (75.26)                                                   
  GOLD FEV1%                          2069                                                0.0133       0.62        0.56 to 0.69     \<0.0001
  FEV1% ≥80                            76             0 (0.0)               76 (100)                                                    
  50 ≤ FEV1% \<80                      643            6 (0.93)            637 (99.07)                                                   
  30 ≤ FEV1% \<50                      959           28 (2.92)            931 (97.08)                                                   
  FEV1% ≤30                            391           13 (3.32)            378 (96.68)                                                   
  GOLD COPD combined assessment       2090                                                \<0.002      0.71        0.67 to 0.75     \<0.0001
  Low risk, low symptom burden         286            1 (0.35)            285 (99.65)                                                   
  Low risk, higher symptom burden      335            4 (1.19)            331 (98.81)                                                   
  High risk, low symptom burden        351            0 (0.00)             351 (100)                                                    
  High risk, higher symptom burden    1118           46 (4.11)            1072 (95.89)                                                  
  HADO score                          1887                                                0.0002       0.68        0.63 to 0.72     \<0.0001
  Mild (\<4)                           188               0                 188 (100)                                                    
  Moderate (5 to 7)                    604            3 (0.50)            601 (99.50)                                                   
  Severe (\>8)                        1095           33 (3.01)            1062 (96.99)                                                  
  ADO index (0 to 14) mean (sd)       2067          11.36 (1.71)          9.29 (2.19)     ≤0.0001      0.78        0.71 to 0.84       0.05

Abbreviations: ADO age, baseline dyspnea, and airflow obstruction; AUC, area under the curve; COPD, chronic obstructive pulmonary disease; DeCOPD, Death in exacerbation of chronic obstructive pulmonary disease; ED, emergency department; FEV, forced expiratory volume; GOLD, Global Initiative for Chronic Obstructive Lung Disease; HADO, health, activity, dyspnea, and airflow obstruction; LTHOT; long-term home oxygen therapy; MRC, Medical Research Council; NIMV, non-invasive mechanical ventilation; PCO~2~ carbon dioxide partial pressure; PO~2~, oxygen partial pressure.

^a^Reference value.

\*p-value of the relationship of each parameter with short-term mortality.

\*\*p-value or the comparison of areas under Receiver Operating Characteristic Curves with respect to the AUC of the DECOPD continuous scale.

Discussion
==========

This study describes the development of a clinical prediction rule for short-term mortality in patients with exacerbations of COPD, derived from a large, multicenter prospective cohort. This rule predicts death using clinical data generally available in the ED, and also often available in the primary care setting. Development of this rule followed proper procedures for derivation and validation \[[@B11],[@B12]\], and the rule provides excellent predictive validity.

Given how common exacerbations are among patients with COPD, and the substantial effects of these exacerbations on health, health-related quality of life, and healthcare costs, predicting the severity of exacerbations could significantly improve both care and allow more targeted allocation of healthcare resources. To date, however, no validated clinical prediction rules are available to stratify all patients experiencing an eCOPD upon their arrival in an ED, or to provide valid and reliable clinical rules or scores for predicting short-term outcomes \[[@B6],[@B9]\].

To the best of our knowledge, no prior prospective cohort studies including both patients admitted to the hospital and those discharged to home from the ED have been employed to develop and validate a clinical prediction rule for death using variables commonly available in the ED \[[@B6],[@B9]\]. Although previous authors have proposed predictive models for death or ICU admission, and some have created severity scores for patients with eCOPD, these did not evaluate such a complete range of variables as in our study, including arterial blood gases and other relevant data from the ED, and this limits their results \[[@B7]-[@B9],[@B25],[@B26]\].

The five factors in our final model---age, previous history of LTHOT or NIMV, use of inspiratory accessory muscles or paradoxical breathing upon ED arrival, altered mental status, and baseline dyspnea---have been observed separately as predictors of poor outcomes in previous studies \[[@B6],[@B8],[@B9],[@B11],[@B26]-[@B28]\]. Age is always a surrogate of other still unknown variables. Previous use of LTHOT or NIMV and the baseline level of dyspnea reflect the basal severity of the patient's COPD. Altered mental status or the use of inspiratory accessory muscles upon arrival in the ED indicate acute cardiopulmonary compromise of the current presentation. Some of the parameters included in our rule are not modifiable, such as age or previous need of LTHOT or NIMV at home, which reflect the fragility of the patient and their disease. Severe baseline dyspnea can be modified through respiratory rehabilitation programs. Even for patients with severe COPD who cannot undertake respiratory rehabilitation, efforts to avoid new exacerbations or readmissions can be conducted through programs such as telemedicine or continuity of care, as has been reported elsewhere \[[@B29]\]. Finally, use of inspiratory accessory muscles or paradoxical breathing and altered level of consciousness reflect the severity of the current exacerbation. These are not permanent but modifiable and, in conjunction with other factors, should alert the ED physician to the severity of the patient's eCOPD and guide appropriate treatment and adequate follow-up.

We found that measurement of arterial blood gases upon ED arrival or at the time a decision is made to hospitalize the patient or discharge them to home from the ED did not add any value to our score. We therefore did not include this measurement in our final model due to the high rate of missing data for this parameter, mainly at ED decision time. Nevertheless, future studies should evaluate the final role of these parameters in our score, although room for improvement in its predictive ability appears to be low.

From a practical point of view, our DeCOPD risk classification allows a clinician to identify patients who could be discharged to home (those with mild eCOPD) from those who should be admitted (severe and very severe eCOPD) because the latter are more likely to have an adverse event or to need intensive treatment and closer follow-up. For patients in the moderate category, further clinical information would be needed in the ED to decide if they should be admitted and if they need intensive treatment.

We compared our score with other rules or parameters used to classify patients with COPD, such as the ADO index, HADO score, GOLD FEV1%, and GOLD COPD combined assessment \[[@B16],[@B21],[@B22],[@B24]\]. In each case, these other scores performed poorly compared with our score. However, we must point out that those rules were created for patients with stable COPD, not those experiencing exacerbations. Tabak *et al*. recently proposed a prediction model derived from a large administrative database of hospitalized patients; their model has AUCs around 0.83, also but requires vital signs upon admission and laboratory results \[[@B10]\].

Our study has several strengths. The prediction rule we propose was created from data prospectively collected from a large (n = 2,487) group of patients experiencing COPD exacerbations recruited from 16 different EDs, each with its own set of guidelines or clinical practices for evaluating and treating patients with eCOPD. This is likely to improve the generalizability of the results. The cohort included both patients admitted to the hospital and patients who were discharged to home. Furthermore, we collected a broad range of clinical variables, many of them from the ED, and tested them in different models. We also strove to properly validate these prediction rules, following best practices for such studies \[[@B13],[@B14]\].

The lack of data for some key variables is the main limitation of our work. In a study such as this, clinical practice in the ED prevails over research requirements. We did not ask ED physicians to modify their clinical practices in any way. Thus, we had to work with the information available. Occasionally this led to missing data, but this did not appear to affect the results. In the case of baseline dyspnea (measured by the MRC scale), for example, we determined that patients with missing data had similar outcomes to those with class 5 baseline dyspnea, and the AUC of the final model was not affected by leaving these patient in the calculations or removing them.

It must also be noted that the patient population was almost entirely comprised of men (97%). Similar gender distributions have been observed in other studies performed in our country \[[@B30]\], which probably reflects the smoking patterns in Spain in the mid-20th century. Although we do not consider this to be a serious limitation, it could affect the generalizability of the results.

Finally, we did not include any biomarkers. At the time this study was conducted, several biomarkers were being evaluated for eCOPD (C-reactive protein, procalcitonin, copeptin, pro-adrenomedullin, pro-endothelin, and B-type natriuretic peptide). However, these were not routinely employed in the ED or in the hospital \[[@B31]\]. Whether these biomarkers add value to scores based on clinical variables will be the aim of future studies.

Conclusions
===========

We developed a clinical prediction rule for a critical outcome, death, for patients attending an ED with eCOPD. The five variables included in our model are easily available in the ED (and also in primary care settings) and the score is easy to estimate. This clinical prediction rule could be employed in the clinical management of patients with eCOPD to guide their treatment and follow-up by in the ED and also by primary care physicians. Future studies are needed for validation of this prediction rule and to further demonstrate its value in clinical practice.
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